LY
Lyell Immunopharma, Inc.
LYEL · NASDAQ
$8.79 +2.69% (+$0.23)
1M -31.75%
Market Cap $215.4M
P/E Ratio -
Div. Yield -
ROE 91.62%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/B 0.92x
P/S 7,977.53x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 33.22%
Rev. growth 92.48%
FCF growth N/A
Profitability
0 /100
Weak Net margin 920,285.00%
Op. margin 711,330.00%
FCF margin 496,189.00%
Quality
0 /100
Poor ROE 91.62%
ROA 79.86%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 5.36x
Debt/Equity 0.16x
Net debt/EBITDA N/A
Stability
21 /100
Unstable Rev. volatility 31.09%
EPS volatility 630.98%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LYEL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lynn Seely
Employees
161
Headquarters
South San Francisco
Upcoming events
10 NOV
Earnings
Upcoming earnings report